BeiGene
BGNE
#921
Rank
โ‚น1.727 T
Marketcap
โ‚น15,789
Share price
0.49%
Change (1 day)
24.63%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -โ‚น1,366

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -โ‚น1,422. In 2022 the company made an earnings per share (EPS) of -โ‚น1,656 a decrease over its 2021 EPS that were of -โ‚น1,300.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-โ‚น1,366-17.53%
2022-โ‚น1,65627.35%
2021-โ‚น1,300-19.96%
2020-โ‚น1,62420.81%
2019-โ‚น1,34531.52%
2018-โ‚น1,022417.57%
2017-โ‚น197.53-37.16%
2016-โ‚น314.36158.95%
2015-โ‚น121.40

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-โ‚น85.48-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น23.08-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA